BiondVax Pharmaceuticals Ltd (TA:BVXV) with its epitope-based multimeric vaccine candidate M-001 is among the leaders in the development of the universal influenza vaccine worldwide. In previous clinical trials M-001 was shown to be consistently safe, immuno-genic and demonstrated synergy with conventional flu vaccines. The readout from the ongoing European Phase II study is imminent, while the initiation of the last Phase IIb study funded by the US National Institutes of Health (NIH), with results likely in H217/H118, will pave the way for partnering and the Phase III programme. We initiate coverage with a valuation of NIS269m ($71m).
Seeking multi-strain, multi-year flu protection
One of the main drawbacks of conventional influenza vaccination is historically low effectiveness, which, according to the US Centers for Disease Control and Prevention (CDC), averaged approximately 40% during the flu seasons from 2004 to 2016 and results partly from a mismatch between circulating influenza strains and those used to manufacture the seasonal vaccine. BiondVax aims to develop a vaccine that would provide multi-strain, multi-year protection against seasonal and pandemic viruses, broad protection for as long as possible.
To read the entire report Please click on the pdf File Below